Loading…
Based on limited metadata with no full letter text available, the FDA issued a warning letter to Virginia Center for Reproductive Medicine, a biologics company, on July 1, 2019. While the specific violations cannot be determined due to the unavailable subject line, the warning indicates regulatory concerns with biologic products or services under the FDA's biologics oversight authority. Without access to the complete letter, the precise nature and scope of the compliance issues remain unknown.